On this page you can find relevant researchs on drug-related health topics, including HIV, hepatitis C, drug and overdose prevention, harm reduction and drug treatment. You can also find our Clinical Guidelines.

Prison-based prescriptions aid Scotland's National Naloxone Programme
Opioid overdose is a major cause of premature mortality not only in eastern Europe but in Scotland, as confirmed by the Global Burden of Disease Study 2015.
EMCDDA Strategy 2025
This strategy sets out an ambitious course of travel for the agency to 2025. It presents a vision to contribute to a healthier and more secure Europe, through better informed drug policy and action.
4 things reporters get terribly wrong about "new" drugs
Much of the coverage of drugs contains misinformation and inaccurate or misleading terminology. This all serves to perpetuate unfounded myths and unhelpful hysteria about these substances.
Harm reduction should address the specific needs of couples who inject drugs
Programmes usually address individuals but most equipment sharing occurs between sexual partners.
HepScot's top ten hints for 2017
As 2017 moved forward, Hepatitis Scotland wrote ten key challenges for the year ahead.
Results of US research suggest all people with chronic HCV need treatment to reduce mortality risk
All people with chronic HCV infection should start therapy with direct-acting antivirals, research published in the online edition of Clinical Infectious Diseases suggests.
Higher incidence of HCV in females compared to males who inject drugs
Women who inject drugs have been shown to have higher incidence of HIV and risk behaviours than men, but there are conflicting reports about hepatitis C virus (HCV) incidence.
Oral direct-acting agent therapy for hepatitis C virus infection: A systematic review
The purpose of this review is to summarize published literature on the efficacy and safety of oral DAAs for treatment of persons with chronic HCV infection.
Urban ED HCV screening programs should be expanded, researchers say
Patients diagnosed with hepatitis C infection in an ED setting can be treated and cured at similar rates as those diagnosed in ambulatory care settings, despite the challenges these patients may face, according to findings published in 'Clinical Infectious Diseases.'
Monitoring hepatitis C treatment uptake in Australia
Initiations of new treatment for chronic hepatitis C during March to September 2016.
Share this on: